

Therapeutische antilichamen voor ernstige auto-immuunziektes en kanker



September 2018

Forward Looking Statements

THIS PRESENTATION HAS BEEN PREPARED BY ARGENX SE (“ARGENX” OR THE “COMPANY”) FOR INFORMATIONAL PURPOSES ONLY AND NOT FOR ANY OTHER PURPOSE. NOTHING CONTAINED IN THIS PRESENTATION IS, OR SHOULD BE CONSTRUED AS, A RECOMMENDATION, PROMISE OR REPRESENTATION BY THE PRESENTER OR THE COMPANY OR ANY DIRECTOR, EMPLOYEE, AGENT, OR ADVISER OF THE COMPANY. THIS PRESENTATION DOES NOT PURPORT TO BE ALL-INCLUSIVE OR TO CONTAIN ALL OF THE INFORMATION YOU MAY DESIRE. THIS PRESENTATION ALSO CONTAINS ESTIMATES AND OTHER STATISTICAL DATA MADE BY INDEPENDENT PARTIES AND BY US RELATING TO MARKET SIZE AND GROWTH AND OTHER DATA ABOUT OUR INDUSTRY. THIS DATA INVOLVES A NUMBER OF ASSUMPTIONS AND LIMITATIONS, AND YOU ARE CAUTIONED NOT TO GIVE UNDUE WEIGHT TO SUCH ESTIMATES.

Safe Harbor: Certain statements contained in this presentation, other than present and historical facts and conditions independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding our investigational product candidates and preclinical studies and clinical trials, and the status, plans, timing of expected data readouts related presentations and related results thereof, including the design of our trials and the availability of data from them, the timing and achievement of our product candidate development activities, future outlooks of operations and financial positions, including potential milestones, business strategy, plans and objectives for future operations. When used in this presentation, the words “anticipate,” “believe,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “objective,” “should,” or the negative of these and similar expressions identify forward-looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Such risks include, but are not limited to: the impact of general economic conditions, market conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense

and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials; our ability to obtain and maintain intellectual property protection for our product candidates; and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation.

Efgartigimod ITP Fase 2 Topline Data

Veilig & duidelijk klinisch effect

Product kandidaat	Doelwit	Indicate	Preclin	Fase 1	Fase 2	Fase 3	Registr.
Eigen producten							
ARGX-113 (efgartigimod)	FcRn	Myasthenia Gravis (MG)	█			█	
		Immune Thrombocytopenia (ITP)	█			█	
		ITP Subcutaneous Formulatie (SC)	█			█	
		Pemphigus Vulgaris (PV)	█			█	
		Chronic Inflammatory (CIDP) Demyelinating Polyneuropathy	█			█	
ARGX-110 (cusatuzumab)	CD70	T-Cell Lymphoma	█			█	
		Acute Myeloid Leukemie	█			█	
ARGX-117	Nieuw complement doelwit	Ernstige Auto-immuun ziektes	█				
Gepartnerde producten							
ARGX-112	IL-22R	Huidinflammaties	█				Tot ~€100mm in milestones & royalties
ARGX-115	GARP	Kanker Immunotherapie	█				\$60mm ontvangen; tot \$625mm milestones & royalties
ARGX-116	ApoC3	Dyslipidemia	█				Double-digit royalties & exclusieve optie om programma in te licentiëren



ITP Topline data
Proof-of-concept voor all patiëntentypes, bovenop gangbare therapiën.

- Efgartigimod veilig voor ITP patiënten
- Klinisch betekenisvolle stijging van bloedplaatjes
- Bevestiging: *pipeline-in-a-product* opportuniteit

- **Innovative Access Program:** 7 live programma's
- Additionele programma's oa:
 - ARGX-111 (c-MET - vaste en bloed kankers) klaar om te partneren
 - ARGX-109 (IL-6 - reumatoid arthritis) gepartnered met Genor Biopharma

Financiering van \$300M

Efgartigimod: Fase 3 ITP, Fase 2 subcutane formulatie & 4^{de} indicatie (CIDP)

Product kandidaat	Doelwit	Indicate	Preclin	Fase 1	Fase 2	Fase 3	Volgende mijlpaal
Eigen producten							
ARGX-113 (efgartigimod)	FcRn	Myasthenia Gravis (MG)					3Q18: Start Fase 3 MG
		Immune Thrombocytopenia (ITP)					ASH18: Volledige dataset Fase 2 ITP
		ITP Subcutaneous Formulatie (SC)					1H19: Start Fase 2 SC Formulatie
		Pemphigus Vulgaris (PV)					1Q19: Topline data Fase 2 PV
		Chronic Inflammatory (CIDP) Demyelinating Polyneuropathy					1H19: Start Fase 2 CIDP
ARGX-110 (cusatuzumab)	CD70	T-Cell Lymphoma					ASH18: Topline data Fase 2 CTCL
		Acute Myeloid Leukemie					ASH18: Full data Fase 1 in AML/MDS
ARGX-117	Nieuw complement doelwit	Ernstige Auto-immuun ziektes					Antilichaam gemedieerde auto-immuun ziektes – complementair met ARGX-113
Gepartnerde producten							
ARGX-112	IL-22R	Huidinflammaties					Tot ~€100mm in milestones & royalties
ARGX-115	GARP	Kanker Immunotherapie					\$60mm ontvangen; tot \$625mm milestones & royalties
ARGX-116	ApoC3	Dyslipidemia					Double-digit royalties & exclusieve optie om programma in te licentiëren

- **Innovative Access Program:** 7 live programma's
- Additionele programma's oa:
 - ARGX-111 (c-MET - vaste en bloed kankers) klaar om te partneren
 - ARGX-109 (IL-6 - reumatoid arthritis) gepartnered met Genor Biopharma

2018 Q1 Q2

ARGX-113

MG Ph2 Full data (AAN, April 24, LA) ✓

PV Ph2 Interim data ✓
SubQ Ph1 HV Full data ✓

ARGX-110

AML Ph2 Launch ✓

Partnerships

ARGX-117 Novel complement target ✓

ARGX-112: LEO Pharma CTA milestone ✓

ARGX-115: AbbVie second preclinical milestone (\$10mm) ✓

2018 Q3 Q4

ARGX-113

MG Ph 3 Launch ✓
ITP Ph2 Topline data ✓

ARGX-110

ITP Ph 2 Full data (ASH)
AML Ph1/2 Full data (ASH)
CTCL Ph2 Full data (ASH)

Partnerships

Shire milestone: Exclusive option ✓

ARGX-115: AbbVie exercised option ✓

Potential milestone(s)



Vragen?
